TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02568761

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection Snoreplasty
Description: Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oropharyngeal Exercises
Description: Myofunctional isometric and isotonic exercises of the soft palate, pharyngeal side walls, face and tongue.
Study: NCT02884024

Intervention type: OTHER
Intervention: no intervention
Description: there is no intervention in this study

Intervention type: OTHER
Intervention: no intervention
Description: there is no intervention in this study

Intervention type: OTHER
Intervention: no intervention
Description: there is no intervention in this study
Study: NCT00269308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic Manual treatment + home exercise ( procedure+behavior)
Description: The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation and mobilization with light soft tissue massage as indicated to facilitate the manual therapy.~Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supervised rehabilitative exercise + home exercise
Description: The rehabilitative exercise program will consist of 20, 1 hour small-group sessions. It is a modification of exercise protocols used in previous studies by the investigators and others and incorporates recommendations of leading rehabilitative exercise specialists. The program will include exercises that reduce joint stiffness and relax elastic structures resulting in lower joint loads during movements.~Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
Study: NCT04301466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qi Zhi Tong Luo capsule
Description: Patients were receiveed Qi Zhi Tong Luo Capsule 4 capsules, 2 times per day for 24 weeks. QZTL capsule, a traditional Chinese medicine. Each capsule was weighted 0.5g.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients were allocated to placebo, 4 capsules, 2 times per day for 24 weeks.To preserve blinding, the placebo had an identical taste and appearance to the experimental drugs. Placebo (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
Study: NCT00743249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINI MONOKA canalicular stent, 10 mm
Description: 40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 10 mm length

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINI MONOKA canalicular stent, 20 mm
Description: 40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 20 mm length
Study: NCT03936608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programming individualized RV-LV pacing offset to optimize ECG
Description: After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. The RV-LV offset that optimizes the paced QRS morphology on ECG will be programmed.
Study: NCT02663518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-0791800 (TTI-621)
Description: Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-0791800 (TTI-621)
Description: Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-0791800 (TTI-621)
Description: Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-0791800 (TTI-621)
Description: Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-0791800 (TTI-621)
Description: Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-0791800 (TTI-621)
Description: Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-0791800 (TTI-621)
Description: Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-0791800 (TTI-621)
Description: Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-0791800 (TTI-621)
Description: Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-0791800 (TTI-621)
Description: Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07901800 (TTI-621) plus Rituximab
Description: Combination therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07901800 (TTI-621) plus Nivolumab
Description: Combination therapy
Study: NCT03936608

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nominally programming CRT device without RV-LV offset
Description: After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. Nominal standard-of-care CRT programming with no RV-LV offset will be programmed.
Study: NCT04546490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure Release technique
Description: Manual therapy technique used by the treatment of Myofsacial Trigger points. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point and increasing the pressure as he perceives a reduction in the resistance offered by the soft tissue under the finger

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure Release technique
Description: Manual therapy technique used by the treatment of Myofsacial Trigger points. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point and increasing the pressure as he perceives a reduction in the resistance offered by the soft tissue under the finger

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic pressure technique
Description: Manual therapy technique by making pressure in Myofascial Trigger Point. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point. This is performed until the patient's tolerance, when he refers a decrease in pain or have a correct adaptation to the perceived pain increase the pressure to a new painful barrier.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic pressure technique
Description: Manual therapy technique by making pressure in Myofascial Trigger Point. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point. This is performed until the patient's tolerance, when he refers a decrease in pain or have a correct adaptation to the perceived pain increase the pressure to a new painful barrier.
Study: NCT01272232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
Study: NCT00353522

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalcetrapib
Description: 900mg po daily for 24 weeks
Study: NCT01940224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Preoperative administration of pregabalin 300mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preoperative administration of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Postoperative administration of morphine via PCA pump for 48h
Study: NCT01272232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Liraglutide placebo of either 3.0 mg or 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
Study: NCT01940224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Postoperative administration of morphine via PCA pump for 48h
Study: NCT02856477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine analysis
Description: a sample of urine is collected during 8 hours.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine analysis
Description: a sample of urine is collected during 8 hours.
Study: NCT05379478

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory assessment of antibody profiles
Description: Antibody profiles will be determined on submitted plasma samples

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory assessment of antibody profiles
Description: Antibody profiles will be determined on submitted plasma samples

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory assessment of antibody profiles
Description: Antibody profiles will be determined on submitted plasma samples
Study: NCT02632435

Intervention type: DEVICE
Group type: OTHER
Intervention: PICC
Description: Participants will be randomized to a PICC for vascular access during chemotherapy.

Intervention type: DEVICE
Group type: OTHER
Intervention: PORT
Description: Participants will be randomized to a PORT for vascular access during chemotherapy
Study: NCT05555966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Activation Mapping Guided Cardiac resynchronization therapy
Description: To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
Study: NCT03850366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: GVHD prophylaxis
Study: NCT01935635

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPDCs-T immune therapy
Description: HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, IV (in the vein), about 2\*105-1\*106 cells per time,total 12 times;
Study: NCT01052103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: 40 milligrams (mg), oral tablets, twice daily: 20 mg in the morning, 20 mg in the evening, for 16 or 17 weeks. The dose may be adjusted to a minimum of 20 mg or a maximum of 80 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablets, twice daily: in the morning and in the evening, for 16 or 17 weeks.
Study: NCT01935635

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPDCs-T immune therapy
Description: HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, IV (in the vein), about 2\*105-1\*106 cells per time,total 12 times;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPDCs-T immune therapy
Description: HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, IV (in the vein), about 2\*105-1\*106 cells per time,total 12 times;
Study: NCT01052103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: United States (U.S.) label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: United States (U.S.) label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)
Study: NCT02143752

Intervention type: BEHAVIORAL
Intervention: Mindfulness
Description: Group behavioral intervention using mindfulness to help smokers quit smoking

Intervention type: BEHAVIORAL
Intervention: Quit Line
Description: see arm
Study: NCT00626132

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Eucommia
Description: two capsules three times a day orally for 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eucommia
Description: two capsules three times a day orally for 2 weeks
Study: NCT00978523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)
Description: Oral, dose-escalation
Study: NCT00434213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daytrana
Description: Methylphenidate Transdermal System (MTS)
Study: NCT01854853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STYLE Brazil
Description: Multifamily group HIV/STI Prevention Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion
Description: Health promotion intervention
Study: NCT01990729

Intervention type: DIETARY_SUPPLEMENT
Intervention: ARTRA
Description: ARTRA (glucosamine and chondroitin sulfate)
Study: NCT03386825

Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Antineoplastic agents, protein kinase inhibitor (L01XE21)

Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Antineoplastic agents, protein kinase inhibitor (L01XE21)

Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Antineoplastic agents, protein kinase inhibitor (L01XE21)
Study: NCT01123876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Subjects will be given Veliparib twice daily on Days 1-5 and 15-19 every 28 days orally
Study: NCT01181323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.2 ml of Intranasal placebo study product (using sucrose phosphate placebo filled sprayers), will be administered to maternal subjects.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cold-adapted live attenuated influenza virus vaccine, trivalent
Description: Licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose LAIV (Flumist®) 0.1 ml administered to maternal subjects intranasally in each nostril for a total of 0.2 mL.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 ml of Sterile saline (0.9 percent Sodium Chloride for injection), administered IM to maternal subjects.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Preservative free, licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose of TIV (Fluzone®) 0.5 ml administered to maternal subjects, IM in the deltoid.
Study: NCT03724773

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-Arm Cast
Description: A long-arm cast is a circumferential wrapping of the arm from the fingers to above the elbow with casting material.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sugar-Tong Splint
Description: A sugar-tong splint is the application of hard splinting material on the front and back of the arm.
Study: NCT03152903

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002 (Recombinant BCG Vaccine)
Description: VPM1002 is a formulated, lyophilized cake of live recombinant Mycobacterium bovis rBCGÄureC::Hly+; VPM1002.~VPM1002 is the active pharmaceutical ingredient. It is a genetically modified BCG vaccine derived from the Mycobacterium bovis BCG subtype Prague characterized as rBCGÄureC::Hly+. Single dose of VPM1002 is administered intradermally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of Placebo is administered intradermally.
Study: NCT01156792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP 100
Description: FP 100mcg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP 100
Description: FP 100mcg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP 100
Description: FP 100mcg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP 100
Description: FP 100mcg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100
Description: GSK2190915 100mg QD (AM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 300
Description: GSK2190915 300mg QD (AM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: montelukast 10mg QD (PM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP/SAL 100/50
Description: FP/SAL 100/50mcg BID
Study: NCT02234687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomaglumetad Methionil 160mg
Description: Pomaglumetad Methionil 160mg, one dose, one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomaglumetad Methionil 40mg
Description: Pomaglumetad Methionil 40mg, one dose, one time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, one dose, one time
Study: NCT03663491

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal Gastroscopy
Description: Use of transnasal endoscopes for routine gastroscopy in adults.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Gastroscopy, unsedated
Description: Use of transoral endoscopes for routine gastroscopy in adults. Use of local anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Gastroscopy, sedated
Description: Use of transoral endoscopes for routine gastroscopy in adults. Use of intravenous sedation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Gastroscopy with transnasal endoscope, sedated
Description: Use of transnasal endoscopes for routine gastroscopy in adults, following a failed attempt to perform transnasal gastroscopy
Study: NCT00965666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: All qualified subjects receive 24 weekly subcutaneous injections of Etanercept.
Study: NCT04087980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Poseidon System
Description: Multicenter Pilot Study of the Poseidon System for the Ablation of Prostate Tissue Utilizing Sterile Water Vapor in Patients with Intermediate Risk Localized Prostate Cancer
Study: NCT03700801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple combination therapy group
Description: Triple oral hypoglycemic therapy based on metformin, dapagliflozin plus saxagliptin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premixed insulin therapy group
Description: Subcutaneous injection therapy with insulin aspart 30 in patients with T2DM
Study: NCT00117637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Multi kinase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon
Description: Interferon
Study: NCT02417883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Evaluate urinary excretion rate fo furosemide
Study: NCT01476007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Cobalamin (vitamin B12)
Description: Intervention group: oral Optovite® B12 1000 gammas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intramuscular Cobalamin (vitamin B12)
Description: Control group: intramuscular Optovite® B12 1000 gammas.
Study: NCT00474955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms or 135 micrograms sc weekly for 48 weeks
Study: NCT00556907

Intervention type: RADIATION
Group type: OTHER
Intervention: Intraoperative radiotherapy
Description: 20Gy to surface of tumor bed and 5Gy at depth of 1cm from surface of tumor bed

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraoperative radiotherapy
Description: 20gy to tumor bed, 5gy at depth of 1cm from surface of tumor bed
Study: NCT01881516

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: once per week for 6 weeks，30 mins for each treatment and for seven main acupoints

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: the same acupoints and time as in acupuncture arm, but use a Park Sham Device
Study: NCT03016572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Follow-Up Calls, Questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Follow-Up Calls, Questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Follow-Up Calls, Questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crisis Intervention
Description: Frontline Services will be administering follow up phone calls for participants of the study, recently discharged from the emergency room.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crisis Intervention
Description: Frontline Services will be administering follow up phone calls for participants of the study, recently discharged from the emergency room.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wraparound Services
Description: Tapestry will be assigning case management services for participants randomized into the third arm of the study.
Study: NCT03767946

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantiferon Gold Plus Test
Description: Small volume of whole blood incubated with specific TB antigen and then dosage of Interferon gamma production.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantiferon Gold Plus Test
Description: Small volume of whole blood incubated with specific TB antigen and then dosage of Interferon gamma production.
Study: NCT03398213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Ear stimulation with plaster
Study: NCT00057629

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure (PE)
Description: Prolonged Exposure (PE) consists of 10 weekly 90-minute treatment sessions, which may be extended up to 20 sessions, depending on client response. Treatment procedures include education about common reactions to trauma, breathing retraining, prolonged (repeated) exposure to trauma memories, repeated in vivo exposure to situations the client is avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises as well as beliefs about self and the world.